VTGN News and Press, VistaGen Therapeutics Inc.

Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...

Mental Health America’s highest national certification enhances Vistagen’s ongoing efforts to promote mental health throughout the U.S. Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization...

2024-06-12 08:52:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips VistaGen Therapeutics (NASDAQ: VTGN ) just reported results for the fourth quarter of 2024. VistaGen Therapeutics reported earnings per share of -25 cents. This was above ...

Vistagen Therapeutics (NASDAQ: VTGN) , a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting financial results for t...

2024-06-11 18:41:02 ET Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Conference Call June 11, 2024 05:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Fina...

2024-06-11 16:23:35 ET More on VistaGen Therapeutics Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiet...

Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3 Phase 3 trial recently initiated; PALISADE-4 Phase 3 trial initiation anticipated in 2H 2024 Vistagen (Nasdaq: VTGN), a neuroscience-f...

Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...

2024-06-10 13:02:56 ET More on VistaGen Therapeutics Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiet...

Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, plans to host a conference call and webcast on Tuesday, June 11, 2024, at 2 p.m. PT (5 p.m. ET). During the confere...